Holistic Skincare Approach of Cleanse-Treat-Moisturize-Protect (CTMP®) in Atopic Dermatitis Management: Indian...

Atopic dermatitis (AD) is a chronic, relapsing inflammatory dermatosis characterized by epidermal barrier dysfunction, immune dysregulation, and significant impairment in quality of life, particularly among pediatric populations. Although topical anti-inflammatory therapies remain central to acute flare control, growing evidence supports barrier-directed skincare as a fundamental component of long-term disease management. This narrative review synthesizes current evidence on cleansing, moisturization, photoprotection, and preventive strategies in AD, with specific consideration of pediatric care and real-world challenges within the Indian healthcare context. Clinical studies consistently demonstrate that regular emollient use enhances skin hydration, accelerates barrier recovery, alleviates symptom burden, and improves quality of life, with additive benefits when combined with topical corticosteroids. National guidance further emphasizes age-appropriate bathing practices, including delayed bathing in low-birth-weight infants and gentle cleansing followed by prompt emollient application. Despite these recommendations, Indian surveys reveal persistent gaps in caregiver awareness, delayed diagnosis, intermittent moisturizer use, and suboptimal adherence driven by cost constraints, loss to follow-up, and preference for alternative therapies. While emerging modalities, including biomimetic formulations, digital health platforms, and personalized skincare, offer potential future directions, current evidence remains largely exploratory, with limited data on cost-effectiveness and real-world implementation. Overall, barrier-focused skincare represents an important adjunct to pharmacologic therapy in AD; however, effective integration into Indian clinical practice will require strengthened caregiver education, context-specific guidance, and system-level strategies addressing accessibility and adherence, supported by future pragmatic trials and epidemiological studies to enable scalable, evidence-based care.